|
|
|
|
|
Stop the Bleeding
|
|
|
|
Manufacturers overpay PBMs millions of dollars each year in rebates overpayments. Here's how to stop the leakage.
|
|
|
|
Global Warming
|
|
|
| By
Walter Armstrong
|
|
|
|
Japan is playing a game of catch-up, dropping big cash on biotechs and risky acquisitions. But with patents expiring and sales falling, can they really pay their way to global success?
|
|
|
|
Evolving Clinical Trials
|
|
|
|
Clinical trials need to change. A recent survey shows that industry should address the research supply chain for the greatest gains in effciency.
|
|
|
|
Getting Personal(ized)
|
|
|
|
Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works.
|
|
|
|
The D-Mab Men
|
|
|
| By
Joanna Breitstein
|
|
|
|
Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug.
|
|
|
|
|
|
|
|
|
Seasoned Leaders
|
|
|
| By
Jim Zuffoletti
|
|
|
|
Enter the Maturity Matrix: the future of KOL management organization.
|
|
|
|
Remodeling Your Sales Force
|
|
|
|
It's management makeover time—and micromanaging is so last year.
|
|
|
|
What's The Buzz
|
|
|
|
What's the buzz all about? Word of mouth is more effective than we think.
|
|
|
|
Getting "Engaged"
|
|
|
|
Web analystics is helping a new generation of pharma web sites get engaged.
|
|
|
|
|
|
|
|
|
Part D Under Attack
|
|
|
| By
Jill Wechsler
|
|
|
|
Congressional leaders ready campaign to curb Medicare drug plans.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Open For Debate
|
|
|
| By
Sarah Houlton
|
|
|
|
Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems
|
|
|
|
|
|
|
|
|
Specialty Sales Gets No Resistance
|
|
|
|
Cubist Pharmaceuticals CEO Michael Bonney has given the company a successful start—and is now predicting the future of drug resistance.
|
|
|
|
|
|
|
|
|
Going for Gold
|
|
|
| By
Sander Flaum
|
|
|
|
Try this one on for size: Multi-tasking isn't the path to greatness
|
|
|
|
|
|
|
|
|
Future Shock
|
|
|
| By
Patrick Clinton
|
|
|
|
A vision of pharma's next business model is starting to emerge. But how do we get from here to there?
|
|
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
